Fairvalue-Calculator Fairvalue-Calculator
EN DE

Anhui Huaheng Biotechnology Co (688639) Fair Value & Analysis

Healthcare · CN · Market cap 5.3B CNY

Price¥21.00
Fair Value¥11.65
Upside-44.5%
Quality95/100
Evidence: High Range ¥8.74 – ¥14.56

Analysis

Anhui Huaheng Biotechnology Co (688639) currently trades at ¥21.00, while our model-based Fair Value estimate is ¥11.65 — implying the stock looks roughly 44.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material monomers, including 1,3-propanediol and succinic acid; and other products, including malic acid and arbutin. Its products are used in daily chemical products, medicine, health and personal care products, cosmetic products, food additives, feeds, animal nutrition, plant nutrition, and functional food and nutrition. The company was formerly known as Anhui Huaheng Biological Engineering Co., Ltd. and changed its name to Anhui Huaheng Biotechnology Co., Ltd. in November 2013. The company was founded in 2005 and is based in Hefei, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.